Emilie Le Rhun1, Evanthia Galanis. 1. aBreast Unit, Department of Medical Oncology, Oscar Lambret Center bNeuro-oncology, Department of Neurosurgery, University Hospital cLille University, Inserm U-1192, Laboratoire de Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM), Lille, France dDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: To review recent original data on leptomeningeal metastases in patients with solid cancer. RECENT FINDINGS: Lung and breast cancer as well as melanoma remain the most common primaries. Advanced cytological methods and targeted sequencing for candidate tumor-specific mutations may improve the sensitivity of cerebrospinal fluid diagnostics in leptomeningeal metastases. Targeted treatments like epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer, anti-human epidermal growth factor receptor-2 treatments for breast cancer or B-rapidly accelerated fibrosarcoma-targeted or immunotherapy for melanoma have an emerging role in the management of this condition. SUMMARY: Novel diagnostic approaches and the introduction of targeted agents may improve the clinical management of patients with leptomeningeal metastases from solid cancers.
PURPOSE OF REVIEW: To review recent original data on leptomeningeal metastases in patients with solid cancer. RECENT FINDINGS: Lung and breast cancer as well as melanoma remain the most common primaries. Advanced cytological methods and targeted sequencing for candidate tumor-specific mutations may improve the sensitivity of cerebrospinal fluid diagnostics in leptomeningeal metastases. Targeted treatments like epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer, anti-humanepidermal growth factor receptor-2 treatments for breast cancer or B-rapidly accelerated fibrosarcoma-targeted or immunotherapy for melanoma have an emerging role in the management of this condition. SUMMARY: Novel diagnostic approaches and the introduction of targeted agents may improve the clinical management of patients with leptomeningeal metastases from solid cancers.
Authors: Emilie Le Rhun; Roberta Rudà; Patrick Devos; Khê Hoang-Xuan; Dieta Brandsma; Pedro Pérez Segura; Riccardo Soffietti; Michael Weller Journal: J Neurooncol Date: 2017-04-28 Impact factor: 4.130
Authors: Syed M Adil; Sarah E Hodges; Ryan M Edwards; Lefko T Charalambous; Zidanyue Yang; Musa Kiyani; Alexis Musick; Beth A Parente; Hui-Jie Lee; Katherine B Peters; Peter E Fecci; Shivanand P Lad Journal: Neurooncol Pract Date: 2020-07-21